Financing Scandinavia; plus IP waivers, Long COVID & AAV pays: a BioCentury podcast

Scandinavia’s appetite for risk and strong foundation in basic research have given the region a robust translational environment and broad interest in investing in life sciences. But does that guarantee success in building globally competitive biotechs? On the latest BioCentury This Week podcast, BioCentury’s editors discuss the biopharma ecosystem in northern Europe, plus waiving IP for COVID-19 vaccines, Long COVID and the financing environment for AAV companies.

Funding for early stage companies isn’t nearly as hard to come by in the Nordic region as elsewhere in Europe, says Executive Editor Jeff Cranmer. That is in part due to the area’s standout institutes, according to BioCentury Editor in Chief Simone Fishburn. ...